hydromorphone

(redirected from Exalgo)
Also found in: Thesaurus, Medical.

hy·dro·mor·phone

 (hī′drō-môr′fōn′)
n.
A synthetic derivative of morphine, C17H19NO3, used in the form of its hydrochloride as an analgesic that is more potent than morphine.

ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.hydromorphone - a narcotic analgesic (trade name Dilaudid) used to treat moderate to severe pain
analgesic, anodyne, pain pill, painkiller - a medicine used to relieve pain
Translations

hydromorphone

n hidromorfona
References in periodicals archive ?
s Exalgo (hydromorphone hydrochloride extended-release tablets 8 mg, 12 mg and 16 mg).
Questcor's primary product, Acthar, will add significant breadth and depth to Mallinckrodt's growing portfolio of specialty brands, which includes EXALGO, Gablofen[sup.
0 million milestone payment from its commercial partner Covidien following the FDA approval of Exalgo on March 1, 2010.
Approved in 2010, Exalgo is an extended-release formulation of hydromorphone indicated for once-daily administration for the management of moderate to severe pain in opioid-tolerant patients who require continuous, around-the-clock opioid analgesia for an extended period.
Therapeutic use: Exalgo is an extended-release oral formulation of hydromorphone (14) indicated for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.
Exalgo is intended to treat moderate to severe pain in patients who require treatment with opioid painkillers for an extended period of time.
The company has recorded sales worth $167 million under specialty pharmaceuticals, reflecting a sound 25% boost from the sales figure of previous year, mostly because of robust presentation by its Exalgo tablets as well as by its generic product portfolio.
This merger brings together the product assets and financial resources of both organizations, including potential Exalgo milestone and royalty revenue, CombinatoRx's portfolio of product candidates and unique drug discovery capabilities.
However, relative ownership of CombinatoRx will be adjusted based upon the outcome of the regulatory review of Neuromed's lead drug candidate Exalgo, a pain drug currently in late-stage clinical trials.
Dublin, Ireland) said it bought the rights to the extended-release opioid painkiller Exalgo from Neuromed Pharmaceuticals Ltd.
A 32mg dosage strength of Exalgo was approved by the FDA in August 2012.